World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
62
Citations
16846
World Ranking
3108
National Ranking
1455

Overview

William Stohl is affiliated with the University of Southern California in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focus on specific subfields including Immunology, Rheumatology, Radiology, Nuclear Medicine and Imaging, Genetics, and Pathology and Forensic Medicine.

The main topics of Stohl's work are thorough and specialized, covering Systemic Lupus Erythematosus Research, T-cell and B-cell Immunology, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, Immune Cell Function and Interaction, Atherosclerosis and Cardiovascular Diseases, and Lymphoma Diagnosis and Treatment.

Stohl has published extensively in various scientific venues. Frequent publication venues include:

  • Annals of the Rheumatic Diseases
  • ACR Open Rheumatology
  • The Lancet Rheumatology
  • The Journal of Immunology
  • American Journal of Reproductive Immunology

Their recent papers illustrate a focus on autoimmune diseases and therapeutic approaches, notably in systemic lupus erythematosus and rheumatoid arthritis. Selected recent papers by Stohl include:

  • Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial (2021, Annals of the Rheumatic Diseases)
  • Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents (2020, Frontiers in Medicine)
  • Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial (2020, The Lancet Rheumatology)
  • Systemic lupus erythematosus (SLE): emerging therapeutic targets (2020, Expert Opinion on Therapeutic Targets)
  • Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus (2022, Arthritis Care & Research)

Collaborations form an integral part of Stohl's research. Frequent coauthors include:

  • Leanna Wise
  • David A. Roth
  • Ning Yu
  • James Cheng-Chung Wei
  • Julia Harris

Best Publications

  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera

  • Elevated serum B lymphocyte stimulator levels in patients with systemic immune–based rheumatic diseases

    Gurtej S. Cheema;Viktor Roschke;David M. Hilbert;William Stohl

  • B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

    William Stohl;Samy Metyas;Soon Min Tan;Gurtej S. Cheema

  • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

    Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse

  • Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus

    Michelle Petri;William Stohl;Winn Chatham;W. Joseph McCune

  • Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

    Roy Fleischmann;Eduardo Mysler;Stephen Hall;Alan J Kivitz

  • Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

    Richard A. Furie;Michelle A. Petri;Daniel J. Wallace;Ellen M. Ginzler

  • Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

    William Stohl;Falk Hiepe;Kevin M. Latinis;Mathew Thomas

  • TGF-β Requires CTLA-4 Early after T Cell Activation to Induce FoxP3 and Generate Adaptive CD4+CD25+ Regulatory Cells

    Song Guo Zheng;Ju Hua Wang;William Stohl;Kyoung Soo Kim

  • Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

    William Stohl;Andreas Schwarting;Masato Okada;Morton Scheinberg

  • Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

    P.P. Tak;W.F. Rigby;A. Rubbert-Roth;C.G. Peterfy

  • BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.

    Viktor Roschke;Svetlana Sosnovtseva;Christopher D. Ward;June S. Hong

  • Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

    Geraldine Cambridge;William Stohl;Maria J. Leandro;Thi-Sau Migone

  • Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

    Richard Furie;William Stohl;Ellen M Ginzler;Michael Becker

  • Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

    Soon-Min Tan;Dong Xu;Viktor Roschke;James W. Perry

  • Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

    J T Merrill;R F van Vollenhoven;J P Buyon;R A Furie

  • B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

    Geraldine Cambridge;David A Isenberg;Jcw Edwards;Maria J Leandro

  • Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

    Noa Schwartz;Tamar Rubinstein;Linda C Burkly;Christopher E Collins;Christopher E Collins

  • Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

    Ellen M. Ginzler;Daniel J. Wallace;Joan T. Merrill;Richard A. Furie

  • B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

    Christopher E Collins;Amanda L Gavin;Thi-Sau Migone;David M Hilbert

Frequent Co-Authors

Chaim Putterman
Chaim Putterman Albert Einstein College of Medicine
Chaim O. Jacob
Chaim O. Jacob University of Southern California
Michael P. Cancro
Michael P. Cancro University of Pennsylvania
David M. Roth
David M. Roth University of California San Diego
Joan T. Merrill
Joan T. Merrill Oklahoma Medical Research Foundation
Daniel J. Wallace
Daniel J. Wallace Cedars-Sinai Medical Center
Song Guo Zheng
Song Guo Zheng Shanghai Jiao Tong University
David A. Horwitz
David A. Horwitz University of Southern California
Michael Koss
Michael Koss ETH Zurich
Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students pursuing immunology, understanding related healthcare degrees can open diverse career opportunities. Many professionals transition into fields requiring advanced nursing skills, such as becoming a Nurse Practitioner. Enrolling in a nurse practitioner accelerated program can fast-track this process for those with prior healthcare experience.

For registered nurses seeking specialization, obtaining an acute care NP certification expands opportunities to care for critically ill patients, which aligns well with immunological expertise.

Those new to nursing may consider starting with online ADN programs for non nurses. Such programs provide a foundational pathway into nursing, enabling further advancement into immunology-related roles.

Career prospects also vary by location and degree level. A Doctor of Nursing Practice (DNP) degree often leads to higher salaries and leadership roles. For detailed regional salary insights, see the doctor of nursing practice salary overview.

Best Scientists Citing William Stohl

Trending Scientists

Recently Published Articles